



SAFETY DATA SHEET

Revision date: 01-Apr-2017

Version: 1.0

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Morphine Sulfate Injection - preservative-free, contains antioxidant (Hospira, Inc.)

Trade Name: Not established

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active used as opioid analgesic

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company

275 North Field Drive

Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited

Horizon

Honey Lane

Hurley

Maidenhead, SL6 6RJ

United Kingdom

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2

Reproductive Toxicity: Category 1B

Effects on or via lactation

Label Elements

Signal Word: Danger

Hazard Statements: H362 - May cause harm to breast-fed children

H360D - May damage the unborn child

H341 - Suspected of causing genetic defects

Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P263 - Avoid contact during pregnancy/while nursing

P264 - Wash hands thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P308 + P313 - IF exposed or concerned: Get medical attention/advice

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 2 of 11

Version: 1.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Morphine Sulfate	64-31-3	200-582-8	Acute Tox. 4 (H302) Repr. 1B (H360D) Lact. (H362) Muta. 2 (H341)	1-2.5
Sodium metabisulfite USP	7681-57-4	231-673-0	Acute Tox. 4 (H302) Eye Dam. 1 (H318)	<1.0
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary
** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 3 of 11

Version: 1.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Medical Conditions Aggravated by Exposure: Identification and/or Section 11 - Toxicological Information.

None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 4 of 11

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium metabisulfite USP

ACGIH Threshold Limit Value (TWA)	5 mg/m ³
Australia TWA	5 mg/m ³
Belgium OEL - TWA	5 mg/m ³
Denmark OEL - TWA	5 mg/m ³
France OEL - TWA	5 mg/m ³
Greece OEL - TWA	5 mg/m ³
Ireland OEL - TWAs	5 mg/m ³
Portugal OEL - TWA	5 mg/m ³
Spain OEL - TWA	5 mg/m ³
Switzerland OEL -TWAs	5 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Sodium hydroxide

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELS - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
Austria OEL - MAKs	7.5 mg/m ³
Belgium OEL - TWA	5 ppm
Bulgaria OEL - TWA	8 mg/m ³
Cyprus OEL - TWA	5 ppm
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 5 of 11

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Germany - TRGS 900 - TWAs	2 ppm 3 mg/m ³
Germany (DFG) - MAK	2 ppm 3.0 mg/m ³
Greece OEL - TWA	5 ppm 7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm 8 mg/m ³
Italy OEL - TWA	5 ppm 8 mg/m ³
Japan - OELs - Ceilings	2 ppm 3.0 mg/m ³
Latvia OEL - TWA	5 ppm 8 mg/m ³
Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Morphine Sulfate

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)
Band (OEB):

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 6 of 11

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
Water for injection			
No data available			
Sodium hydroxide			
No data available			
HYDROCHLORIC ACID			
No data available			
Morphine Sulfate			
No data available			
Sodium metabisulfite USP			
No data available			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):	No data available		
Flammability (Solids):	No data available		
Flash Point (Liquid) (°C):	No data available		
Upper Explosive Limits (Liquid) (% by Vol.):	No data available		
Lower Explosive Limits (Liquid) (% by Vol.):	No data available		

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 7 of 11

Version: 1.0

10. STABILITY AND REACTIVITY

Possibility of Hazardous Reactions

Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May be harmful if swallowed. May cause eye irritation (based on components)
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.
Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium hydroxide

Mouse IP LD50 40 mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Morphine Sulfate

Rat Oral LD50 461 mg/kg

Rat Para-periosteal LD50 70mg/kg

Rat Intraperitoneal LD50 235mg/kg

Mouse Oral LD50 600mg/kg

Mouse Intravenous LD50 156mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Morphine Sulfate

18 Week(s) Rat Oral 60 g/kg LOAEL Lungs

15 Day(s) Rat Subcutaneous 3144 mg/kg LOAEL Kidney, Ureter, Bladder

9 Week(s) Rat Subcutaneous 3150 mg/kg LOAEL

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 8 of 11

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Morphine Sulfate

Embryo / Fetal Development	Mouse	Subcutaneous	0.15 mg/kg	LOAEL	Teratogenic
Embryo / Fetal Development	Hamster	Subcutaneous	35 mg/kg	LOAEL	Teratogenic
Embryo / Fetal Development	Mouse	Oral	200 mg/kg	LOAEL	Teratogenic
Embryo / Fetal Development	Rat	Subcutaneous	35 mg/kg	LOAEL	Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames)	Salmonella	Negative
In Vivo Micronucleus	Rat	Negative

Morphine Sulfate

In Vivo Micronucleus	Mouse	Positive
In Vivo Chromosome Aberration	Mouse Lymphocytes	Positive
In Vitro Direct DNA Damage	Human Lymphocytes	Positive
In Vitro Chromosome Aberration	Mouse	Negative
Dominant Lethal Assay	Drosophila	Negative

Carcinogen Status: See below

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

Sodium metabisulfite USP

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 9 of 11

Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Morphine Sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
U.S. Drug Enforcement Administration:	Schedule II
Australia (AICS):	Present
EU EINECS/ELINCS List	200-582-8

Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Sodium metabisulfite USP

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	231-673-0

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 10 of 11

Version: 1.0

15. REGULATORY INFORMATION

Sodium hydroxide

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	231-595-7

Additional Information:

U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule II

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: New data sheet.

Revision date: 01-Apr-2017
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

SAFETY DATA SHEET

Material Name: Morphine Sulfate Injection - preservative-free,
contains antioxidant (Hospira, Inc.)
Revision date: 01-Apr-2017

Page 11 of 11

Version: 1.0

End of Safety Data Sheet